A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

Psoriasis Clinical Trial

— CIMPASI-2  

Official title:

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02326272
• Other study ID #: PS0002
• Secondary ID: 2014-003486-14
• Status: Completed
• Phase: Phase 3
• Start date: December 15, 2014
• Est. completion date: September 12, 2018

Study information

• Verified date: September 2019
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.

Description:

This study consists of the following Periods:

• Initial Treatment Period from Week 0 to Week 16

• Maintenance Treatment Period from Week 16 to Week 48

• Open-label Treatment Period from Week 48 to Week 144

• Safety Follow-Up Period from Week 144 to Week 152

Recruitment information / eligibility

• Status: Completed
• Enrollment: 227
• Est. completion date: September 12, 2018
• Est. primary completion date: January 5, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provided informed consent

• Adult men or women >= 18 years

• Chronic plaque psoriasis for at least 6 months

• Baseline psoriasis activity and severity index >= 12 and body surface area >= 10 % and Physician's Global Assessments score >= 3

• Candidate for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy

• Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

• Erythrodermic, guttate, generalized pustular form of psoriasis

• History of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in the protocol

• Congestive heart failure

• History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease

• Concurrent malignancy or a history of malignancy as described in the protocol

• History of, or suspected, demyelinating disease of the central nervous system (e.g., multiple sclerosis or optic neuritis)

• Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 3 months following last dose of study drug. Male subjects who are planning a partner pregnancy during the study or within 10 weeks following the last dose

• Any other condition which, in the Investigator's judgment, would make the subject unsuitable for participation in the study

• Other protocol-defined exclusion criteria may apply

Related Conditions & MeSH terms

• Plaque Psoriasis
• Psoriasis

Intervention

Biological:
• Certolizumab Pegol
Active Substance: Certolizumab Pegol Pharmaceutical Form: Solution for injection in pre-filled syringe Concentration: 200 mg/mL Route of Administration: Subcutaneous use

Other:
• Placebo
Active Substance: Placebo Pharmaceutical Form: Solution for injection in pre-filled syringe Concentration: 0.9 % saline Route of Administration: Subcutaneous use

Locations

Country	Name	City	State
Austria	Ps0002 253	Graz	Steiermark
Canada	Ps0002 221	Barrie	Ontario
Canada	Ps0002 223	London	Ontario
Canada	Ps0002 222	Peterborough	Ontario
Canada	Ps0002 220	Richmond Hill	Ontario
Canada	Ps0002 224	Waterloo	Ontario
Poland	Ps0002 230	Kielce	Swietokrzyskie
Poland	Ps0002 232	Krakow	Malopolskie
Poland	Ps0002 231	Wroclaw
United States	Ps0002 214	Bakersfield	California
United States	Ps0002 205	Cleveland	Ohio
United States	Ps0002 202	East Windsor	New Jersey
United States	Ps0002 201	Greer	South Carolina
United States	Ps0002 210	New York	New York
United States	Ps0002 204	Ormond Beach	Florida
United States	Ps0002 203	Phoenix	Arizona
United States	Ps0002 200	Portland	Oregon
United States	Ps0002 207	Portsmouth	New Hampshire
United States	Ps0002 213	Richmond	Virginia
United States	Ps0002 206	Rochester	New York
United States	Ps0002 208	San Antonio	Texas
United States	Ps0002 212	Santa Monica	California
United States	Ps0002 209	Wilmington	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
UCB Biopharma S.P.R.L.

Countries where clinical trial is conducted

United States,  Austria,  Canada,  Poland, 

References & Publications (1)

Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, pl — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Participants Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16	The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale) and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0=no disease, the maximum score is 72=maximal disease.	Week 16
Primary	Proportion of Participants Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 16	The Investigator assessed the overall severity of Psoriasis (PSO) using the following 5-point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.	Week 16
Secondary	Proportion of Participants Who Achieve a Psoriasis Activity and Severity Index (PASI90) Response at Week 16	The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale) and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0=no disease, the maximum score is 72=maximal disease.	Week 16
Secondary	Proportion of Participants Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 48	The Investigator assessed the overall severity of Psoriasis (PSO) using the following 5-point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.	Week 48
Secondary	Proportion of Participants Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 48	The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale) and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0=no disease, the maximum score is 72=maximal disease.	Week 48
Secondary	Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16	The DLQI is a subject-reported questionnaire designed for use in adult subjects with PSO. The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL). This instrument asks subjects about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. It has been shown to be valid and reproducible in PSO patients. The DLQI score ranges from 0 to 30 with higher scores indicating lower HRQoL. A higher than or equal to (>=) 4-point change in the DLQI score (DLQI response) has been reported to be meaningful for the patient (within-patient minimal important difference Basra et al, 2015) a DLQI absolute score of lower than or equal to (=<) 1 indicates DLQI remission (i.e., no or small impact of the disease on HRQoL).	Week 16

External Links

•   FDA Safety Alerts and Recalls
•   Product Information